Beneficial effects of 20(S)‑protopanaxadiol on antitumor activity and toxicity of cyclophosphamide in tumor‑bearing mice

Lin,Guangzhu; Yu,Xiaofeng; Wang,Jing; Qu,Shaochun; Sui,Dayuan

doi:10.3892/etm.2012.820

Beneficial effects of 20(S)‑protopanaxadiol on antitumor activity and toxicity of cyclophosphamide in tumor‑bearing mice

Authors:
- Guangzhu Lin
- Xiaofeng Yu
- Jing Wang
- Shaochun Qu
- Dayuan Sui
View Affiliations

Affiliations: Department of Pharmacology, School of Pharmacy, Jilin University, Changchun 130021, P.R. China, Department of Respiratory Medicine, China‑Japan Union Hospital, Jilin University, Changchun 130021, P.R. China
Published online on: November 20, 2012 https://doi.org/10.3892/etm.2012.820
Pages: 443-447

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

20(S)‑protopanaxadiol (PPD) is an extract of Panax quinquefolius L. The aim of this study was to investigate the effect of PPD on the antitumor activity and toxicity of cyclophosphamide (CTX) in tumor‑bearing mice. C57BL/6 mice bearing Lewis lung carcinoma cells were treated with PPD (50 mg/kg) alone, CTX (20 mg/kg) alone or PPD (50 mg/kg) in combination with CTX (20 mg/kg), respectively. The results showed that PPD alone has no significant antitumor activity but synergistically enhanced the antitumor activity of CTX. PPD significantly increased the peripheral white blood cell count, bone marrow cell count, interleukin‑2 and interferon‑γ in CTX‑treated tumor‑bearing mice. The lowered levels of spleen index, splenocyte proliferation and natural killer cell activity in tumor‑bearing mice following CTX treatment were also increased by PPD administration. PPD may be a beneficial supplement during CTX chemotherapy for enhancing the antitumor efficacy and reducing the toxicity of CTX.

View Figures

View References

1.	Pass GJ, Carrie D, Boylan M, et al: Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. Cancer Res. 65:4211–4217. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Papaldo P, Lopez M, Marolla P, et al: Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol. 23:6908–6918. 2005. View Article : Google Scholar
3.	Pratheeshkumar P and Kuttan G: Ameliorative action of Vernonia cinerea L. on cyclophosphamide-induced immunosuppression and oxidative stress in mice. Inflammopharmacology. 18:197–207. 2010.
4.	Iyer R, Evans A, Qi X, Ho R, Minturn J, Zhao H, Balamuth N, Maris J and Brodeur G: Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res. 16:1478–1485. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Wang T, Yu X, Qu S, Xu H, Han B and Sui D: Effect of ginsenoside Rb3 on myocardial injury and heart function impairment induced by isoproterenol in rats. Eur J Pharmacol. 636:121–125. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev. 9:259–274. 2004.
7.	Yun TK: Panax ginseng - a non-organ-specific cancer preventive? Lancet Oncol. 2:49–55. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Wang CZ, Du GJ, Zhang Z, et al: Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer. Int J Oncol. 40:1970–1976. 2012.PubMed/NCBI
9.	Kaneko H and Nakanishi K: Proof of the mysterious efficacy of ginseng: basic and clinical trials: clinical effects of medical ginseng, korean red ginseng: specifically, its anti-stress action for prevention of disease. J Pharmacol Sci. 95:158–162. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Wang T, Fu F, Zhang L, Han B, Zhu M and Zhang X: Effects of escin on acute inflammation and the immune system in mice. Pharmacol Rep. 61:697–704. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Tsai YC and Won SJ: Effects of tramadol on T lymphocyte proliferation and natural killer cell activity in rats with sciatic constriction injury. Pain. 92:63–69. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Robak T, Lech-Maranda E and Robak P: Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 10:1529–1543. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Mebius RE and Kraal G: Structure and function of the spleen. Nat Rev Immunol. 5:606–616. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Koehn T, Trimble L, Alderson K, Erbe A, McDowell K, Grzywacz B, Hank J and Sondel P: Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol. 3:912012. View Article : Google Scholar
15.	Ljunggren HG and Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 7:329–339. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Smyth MJ, Cretney E, Kershaw MH and Hayakawa Y: Cytokines in cancer immunity and immunotherapy. Immunol Rev. 202:275–293. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Wang G, Zhao J, Liu J, Huang Y, Zhong JJ and Tang W: Enhancement of IL-2 and IFN-gamma expression and NK cells activity involved in the anti-tumor effect of ganoderic acid Me in vivo. Int Immunopharmacol. 7:864–870. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 3:133–146. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Boehm U, Klamp T, Groot M and Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol. 15:749–795. 1997. View Article : Google Scholar : PubMed/NCBI
20.	Lee J and Lim KT: SJSZ glycoprotein (38 kDa) modulates expression of IL-2, IL-12, and IFN-γ in cyclophosphamide-induced Balb/c. Inflamm Res. Jul 20–2012.(Epub ahead of print).